Finance

Beta
Lists
RCKT:NASDAQ
Rocket Pharmaceuticals Inc
$3.46
+3.28%
(+0.11) 1D
$3.46
0.00% (0.00)
After hours
Closed: Jun 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCKT...
Open
$3.38
High
$3.50
Low
$3.35
Mkt. cap
377.81M
Avg. vol.
2.80M
Volume
2.43M
52-wk high
$5.45
52-wk low
$2.40
EPS
-$1.88
Beta
0.48
Shares outstanding
109.19M
No. of employees
202
Open
$3.38
High
$3.50
Low
$3.35
Mkt. cap
377.81M
Avg. vol.
2.80M
Volume
2.43M
52-wk high
$5.45
52-wk low
$2.40
EPS
-$1.88
Beta
0.48
Shares outstanding
109.19M
No. of employees
202
News stories
From sources across the web
About Rocket Pharmaceuticals Inc
CEO-
Employees202
Founded1999
HeadquartersCranbury, New Jersey, United States
SectorBiotechnology
Websiterocketpharma.com
Analyst Ratings
Based on 11 analysts giving stock ratings to RCKT in the past 3 months
Buy
Buy
5
Hold
4
Sell
2
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for RCKT in the last 3 months.
Highest
Current $3.46
$16.00 (+362.43%)
Average
$9.75 (+181.79%)
Lowest
$3.00 (-13.29%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Jason Zemansky
Bank of America Securities
Buy
Maintained
$10.00
+189%
06/11/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
05/10/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$11.00
+217.9%
05/10/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$10.00
+189%
05/07/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$12.00
+246.8%
05/09/2026
Yun Zhong
Wedbush
Buy
Reiterated
$16.00
+362.4%
05/08/2026
Gil Blum
Needham
Hold
Maintained
-
-
05/08/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
04/02/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
$11.00
+217.9%
03/27/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$3.00
-13.3%
03/27/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
$5.00
+44.5%
03/27/2026
Unknown Analyst
Canaccord Genuity
Buy
Maintained
$10.00
+189%
03/02/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$10.00
+189%
02/27/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
42.66M
34.07M
29.35M
31.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25.02M
18.35M
14.68M
17.06M
Operating expense
67.68M
52.42M
44.03M
48.51M
Total operating expenses
67.68M
52.42M
44.03M
48.51M
Operating income
-67.68M
-52.42M
-44.03M
-48.51M
Other non operating income
-
-
-
-
EBT including unusual items
-68.92M
-50.33M
-42.54M
-47.59M
EBT excluding unusual items
-67.67M
-52.18M
-43.81M
-48.82M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-68.92M
-50.33M
-42.54M
-47.59M
Net profit margin
-
-
-
-
Earnings per share
-0.59
-0.45
-0.38
-0.42
Interest and investment income
483.00K
709.00K
690.00K
161.00K
Interest expense
-473.00K
-473.00K
-473.00K
-473.00K
Net interest expenses
10.00K
236.00K
217.00K
-312.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-65.10M
-49.18M
-41.81M
-46.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer